269 related articles for article (PubMed ID: 19576124)
1. [A new prognostic stratification for patients with acute myeloid leukemia].
Jiang B; Mi YC; Lin D; Cai XJ; Fu MW; Li W; Wang Y; Liu XP; Xue YP; Bian SG; Wang JX
Zhonghua Nei Ke Za Zhi; 2009 Apr; 48(4):316-20. PubMed ID: 19576124
[TBL] [Abstract][Full Text] [Related]
2. A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.
Haferlach T; Kern W; Schoch C; Schnittger S; Sauerland MC; Heinecke A; Büchner T; Hiddemann W;
Haematologica; 2004 Apr; 89(4):408-18. PubMed ID: 15075074
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia.
Xiao Z; Xue H; Li R; Zhang L; Yu M; Hao Y
Am J Hematol; 2008 Mar; 83(3):203-5. PubMed ID: 17874451
[TBL] [Abstract][Full Text] [Related]
4. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
[TBL] [Abstract][Full Text] [Related]
5. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
[TBL] [Abstract][Full Text] [Related]
6. [Proportion of CD34(+)CD38(-) cell population in bone marrow of patients with de novo AML as prognostic factor of complete remission at first course of induction chemotherapy].
Zhang CP; Wei H; Wang HJ; Huai L; He K; Chen YR; Lin D; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1268-72. PubMed ID: 22040986
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].
Shao B; Gao YR; Wang C; Yan SK; Cai Q; Jiang JL; Yang J; Bai HT; Zhao M; Zhao CX
Ai Zheng; 2006 Aug; 25(8):1007-12. PubMed ID: 16965684
[TBL] [Abstract][Full Text] [Related]
9. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
Kern W; Haferlach T; Schoch C; Loffler H; Gassmann W; Heinecke A; Sauerland MC; Berdel W; Buchner T; Hiddemann W
Blood; 2003 Jan; 101(1):64-70. PubMed ID: 12393605
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow morphology during induction phase of therapy for acute myeloid leukemia (AML).
Dick FR; Burns CP; Weiner GJ; Heckman KD
Hematol Pathol; 1995; 9(2):95-106. PubMed ID: 7559259
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic value of early treatment response in children with acute myeloid leukemia].
Tie LJ; Gu LJ; Song DL; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Chen J; Wang YP; Zou JY
Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(26):1837-40. PubMed ID: 17054861
[TBL] [Abstract][Full Text] [Related]
13. In situ RHAMM protein expression in acute myeloid leukemia blasts suggests poor overall survival.
Tzankov A; Strasser U; Dirnhofer S; Menter T; Arber C; Jotterand M; Rovo A; Tichelli A; Stauder R; Günthert U
Ann Hematol; 2011 Aug; 90(8):901-9. PubMed ID: 21274712
[TBL] [Abstract][Full Text] [Related]
14. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
Creutzig U; Büchner T; Sauerland MC; Zimmermann M; Reinhardt D; Döhner H; Schlenk RF
Cancer; 2008 Feb; 112(3):562-71. PubMed ID: 18076087
[TBL] [Abstract][Full Text] [Related]
15. A method comparison study of flow cytometry and cytomorphology to determine the percentages of blasts in patients with acute leukemia after induction and consolidation chemotherapy.
Wongprajun S; Auewarakul CU
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S157-64. PubMed ID: 20364570
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.
Krauter J; Wagner K; Schäfer I; Marschalek R; Meyer C; Heil G; Schaich M; Ehninger G; Niederwieser D; Krahl R; Büchner T; Sauerland C; Schlegelberger B; Döhner K; Döhner H; Schlenk RF; Ganser A
J Clin Oncol; 2009 Jun; 27(18):3000-6. PubMed ID: 19380453
[TBL] [Abstract][Full Text] [Related]
17. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
18. The percentage of peripheral blood blasts on day 7 of induction chemotherapy predicts response to therapy and survival in patients with acute myeloid leukemia.
Gao S; Tan Y; Liu X; Su L; Yu P; Han W; Cui J; Li W
Chin Med J (Engl); 2014; 127(2):290-3. PubMed ID: 24438618
[TBL] [Abstract][Full Text] [Related]
19. [The prognostic significance of regular bone marrow aspirations during induction chemotherapy in acute myeloid leukemia].
Mi Y; Bian S; Xue Y; Zhao Y; Meng Q; Guo Y; Li R; Qin T
Zhonghua Xue Ye Xue Za Zhi; 1997 Jun; 18(6):305-7. PubMed ID: 15622625
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of prognostic variables in childhood acute myeloid leukemia].
Gu LJ; Tie LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Ye H; Wang YP; Dong L
Zhonghua Xue Ye Xue Za Zhi; 2006 Jan; 27(1):10-3. PubMed ID: 16732931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
